VYNE Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
YARW$15.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash Flows From Operating Activities: | ||
| Net loss | $(39,834) | $(28,452) |
| Adjustments required to reconcile net loss to net cash used inoperating activities: | ||
| Depreciation | 4 | — |
| Share-based compensation | 3,303 | 3,305 |
| Amortization of premium or discount on marketable securities | (2,443) | (255) |
| Unrealized (losses) gains on cash equivalents | (1) | 1 |
| Changes in operating assets and liabilities: | ||
| Trade receivables, prepaid expenses and other current assets and operating lease right of use assets | (899) | 405 |
| Trade payables, accrued expenses, employee related obligations and other long-term liabilities | 6,012 | (559) |
| Operating lease liabilities | (114) | 214 |
| Net cash used in operating activities | (33,972) | (25,341) |
| Cash Flows From Investing Activities: | ||
| Purchase of property and equipment | (117) | — |
| Proceeds from the sale of the MST Franchise | — | 5,000 |
| Proceeds from the sale and maturity of marketable securities | 84,000 | — |
| Purchases of marketable securities | (60,518) | (62,354) |
| Net cash provided by (used in) investing activities | 23,365 | (57,354) |
| Cash Flows From Financing Activities: | ||
| Proceeds related to the issuance of common shares and pre-funded warrants through private placement, net of issuance costs | — | 82,665 |
| Proceeds related to the issuance of common shares through at-the-market offerings, net of issuance costs | — | 156 |
| Redemption of convertible preferred stock | — | (360) |
| Withholdings from exercise of options and issuance of shares for share-based compensation arrangements, net | (141) | (67) |
| Net cash (used in) provided by financing activities | (141) | 82,394 |
| Decrease in cash, cash equivalents and restricted cash | (10,748) | (301) |
| Cash, cash equivalents and restricted cash at beginning of the year | 30,674 | 30,975 |
| Cash, cash equivalents and restricted cash at end of the year | $19,926 | $30,674 |
| Cash and cash equivalents | 19,926 | 30,620 |
| Restricted cash | — | 54 |
| Total cash, cash equivalents and restricted cash | $19,926 | $30,674 |
F - 5
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Supplementary information on investing and financing activities not involving cash flows: | ||
| Accretion of preferred stock | $— | $149 |
| Issuance of vested shares under employee share purchase plan | $30 | $48 |
| Additions to operating lease right of use assets | $— | $207 |
| Additions to operating lease liabilities | $— | $214 |
F - 6
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.